IN2014DN04587A - - Google Patents

Info

Publication number
IN2014DN04587A
IN2014DN04587A IN4587DEN2014A IN2014DN04587A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A IN 4587DEN2014 A IN4587DEN2014 A IN 4587DEN2014A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A
Authority
IN
India
Prior art keywords
compounds
methods
administering
acceptable salts
compositions containing
Prior art date
Application number
Other languages
English (en)
Inventor
Chang H Ahn
Won J Choi
Young B Lee
Lak S Jeong
Sang K Lee
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of IN2014DN04587A publication Critical patent/IN2014DN04587A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
IN4587DEN2014 2004-04-01 2005-04-01 IN2014DN04587A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55814104P 2004-04-01 2004-04-01
PCT/US2005/011313 WO2005097757A2 (en) 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof

Publications (1)

Publication Number Publication Date
IN2014DN04587A true IN2014DN04587A (fi) 2015-07-10

Family

ID=34979006

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4587DEN2014 IN2014DN04587A (fi) 2004-04-01 2005-04-01

Country Status (15)

Country Link
US (1) US7405214B2 (fi)
EP (1) EP1732902B1 (fi)
JP (2) JP5001832B2 (fi)
KR (1) KR100926596B1 (fi)
CN (2) CN102091072A (fi)
AT (1) ATE453628T1 (fi)
AU (1) AU2005230676B2 (fi)
BR (1) BRPI0509553B8 (fi)
CA (1) CA2562965C (fi)
DE (1) DE602005018620D1 (fi)
ES (1) ES2334803T3 (fi)
IN (1) IN2014DN04587A (fi)
MX (1) MXPA06011141A (fi)
PL (1) PL1732902T3 (fi)
WO (1) WO2005097757A2 (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315534B2 (en) * 2007-08-10 2016-04-19 Board Of Regents Of The University Of Nebraska Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents
AU2010336357B2 (en) * 2009-12-23 2015-04-16 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
AU2014232502B8 (en) 2013-03-15 2018-01-18 Rexahn Pharmaceuticals, Inc. Process for the preparation of 4-amino-1-((1S,4R, 5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one
MX2017015984A (es) * 2015-06-09 2018-08-15 Rexahn Pharmaceuticals Inc Metodos de usar fluorociclopentenilcitosina.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187674A (ja) * 1984-10-06 1986-05-06 Yoshitomi Pharmaceut Ind Ltd シクロペンテン環を有する新規ヌクレオシド
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
PT1411954E (pt) 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds

Also Published As

Publication number Publication date
PL1732902T3 (pl) 2010-06-30
EP1732902A2 (en) 2006-12-20
CN1980898A (zh) 2007-06-13
KR20070012685A (ko) 2007-01-26
US7405214B2 (en) 2008-07-29
CA2562965A1 (en) 2005-10-20
JP2007531736A (ja) 2007-11-08
BRPI0509553B1 (pt) 2019-06-18
ATE453628T1 (de) 2010-01-15
EP1732902B1 (en) 2009-12-30
JP2012107072A (ja) 2012-06-07
CA2562965C (en) 2013-10-29
BRPI0509553A (pt) 2007-09-18
KR100926596B1 (ko) 2009-11-11
CN1980898B (zh) 2011-01-12
DE602005018620D1 (de) 2010-02-11
ES2334803T3 (es) 2010-03-16
WO2005097757A2 (en) 2005-10-20
MXPA06011141A (es) 2007-08-14
CN102091072A (zh) 2011-06-15
BRPI0509553B8 (pt) 2021-05-25
JP5001832B2 (ja) 2012-08-15
US20050222185A1 (en) 2005-10-06
WO2005097757A3 (en) 2005-12-08
AU2005230676A1 (en) 2005-10-20
AU2005230676B2 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
TW200612936A (en) Indole derivatives
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
TW200510301A (en) Novel compounds
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MXPA06014721A (es) Derivados de alquinilo como moduladores de los receptores de glutamato metabotropico.
ATE530519T1 (de) Cyclobutylaminderivate
TW200407305A (en) Novel compounds
SE0202241D0 (sv) Novel Compounds
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
TW200626158A (en) Naphthaline derivatives
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
MX2010013682A (es) Derivados de 2,4-diamino-l,3,5-triazina triciclicos utiles para el tratamiento del cancer y trastornos mieloproliferativos.
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
TW200637817A (en) 5-aminoindole derivatives
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns